A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Tumors Clinical Trial

Official title:

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02501096
• Other study ID #: E7080-A001-111
• Secondary ID: 2017-000300-26
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: July 22, 2015
• Est. completion date: July 11, 2022

Study information

• Verified date: June 2022
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous [IV], every 3 weeks [Q3W]) pembrolizumab in participants with selected solid tumors (i.e. non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma). Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 7 cohorts at the MTD from Phase 1b (lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W, IV).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 357
• Est. completion date: July 11, 2022
• Est. primary completion date: August 18, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Phase 1b: Histologically and/or cytologically confirmed metastatic selected solid tumor types that have progressed after treatment with approved therapies or for which there are no standard effective therapies available. If nivolumab or pembrolizumab is an approved therapy for the participant's tumor type, but the participant has not been treated with it, the Investigator may enroll the participant in this study.

Phase 2: Histologically and/or cytologically confirmed metastatic selected solid tumor types with 0-2 prior lines of systemic therapy. If previously treated, participant has progressed after previous treatment. For the non-small cell lung cancer (NSCLC) and melanoma cohorts, participants must have progressed on or after prior treatment with one anti-programmed cell death protein 1 (anti-PD-1), anti-PD-1 ligand 1 (anti-PD-L1), or anti-PD-1 ligand 2 (anti-PD-L2) agent. For the renal cell carcinoma (RCC) cohort, participants must have progressed on treatment with an anti- programmed death receptor-1 /programmed death receptor-ligand 1 monoclonal antibody (anti-PD-1/PD-L1 mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies, the regimen with an anti-PD-1/PD-L1 mAb must be the most recent therapy. Selected tumor types of both phases: NSCLC, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal melanoma)

2. Life expectancy of 12 weeks or more

3. Phase 2: Measurable disease meeting the following criteria:

1. At least 1 lesion of greater than or equal to 10 mm in the longest diameter for a non-lymph node or greater than or equal to 15 mm in the short-axis diameter for a lymph node that is serially measurable according to irRECIST (immune-related Response Evaluation Criteria in Solid Tumors) using computerized tomography/magnetic resonance imaging (CT/MRI)

2. Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show subsequent evidence of substantial size increase to be deemed a target lesion

4. Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1

5. Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal to 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Cycle 1 Day 1

6. Adequate renal function defined as creatinine less than or equal to 1.5*ULN (upper limit of normal) or calculated creatinine clearance greater than or equal to 40 mL/min per the Cockcroft and Gault formula with creatinine levels greater than 1.5*ULN

7. Adequate bone marrow function:

1. Absolute neutrophil count (ANC) greater than or equal to 1500/mm3 (greater than or equal to 1.5 X 103/uL)

2. Platelets greater than or equal to 100,000/mm3 (greater than or equal to 100 X 109/L)

3. Hemoglobin greater than or equal to 9.0 g/dL

8. Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to 1.5

9. Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the ULN and alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3*ULN (in the case of liver metastases less than or equal to 5*ULN). In case ALP is greater than 3 X ULN (in the absence of liver metastases) or greater than 5 X ULN (in the presence of liver metastases) AND the participant also is known to have bone metastases, the liver specific ALP must be separated from the total and used to assess the liver function instead of the total ALP

10. Males or females age greater than or equal to 18 years at the time of informed consent

11. Participants with known brain metastases will be eligible if they have completed the primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection) and if they have remained clinically stable, asymptomatic and off of steroids for at least 28 days before starting study treatment.

12. All females must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin [ß-hCG]) at the Screening Visit and the Baseline Visit. A pregnancy test needs to be performed within 72 hours of the first dose of study drug. Females of childbearing potential must agree to use a highly effective method of contraception for the entire study period and for 120 days after study discontinuation, ie

• total abstinence (if it is their preferred and usual lifestyle)

• an intrauterine device (IUD) or hormone-releasing system (IUS)

• a contraceptive implant

• an oral contraceptive** (with additional barrier method) OR

• have a vasectomized partner with confirmed azoospermia.

NOTES:

• All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).

• Must be on a stable dose of the same oral hormonal contraceptive product for at least 4 weeks before dosing with study drug and for the duration of the study

13. Male participants who are partners of women of childbearing potential must use a condom + spermicide and their female partners if of childbearing potential must use a highly effective method of contraception (see methods described in Inclusion Criterion #12) beginning at least 1 menstrual cycle prior to starting study drug(s), throughout the entire study period, and for 120 days after the last dose of study drug, unless the male participants are totally sexually abstinent or have undergone a successful vasectomy with confirmed azoospermia or unless the female partners have been sterilized surgically or are otherwise proven sterile.

14. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol

15. Archival tumor tissue or a newly obtained biopsy must be available prior to the first dose of study drug for biomarker analysis. In the case archival tissue cannot be provided, participants with inaccessible tumors for biopsy specimens can be enrolled without a biopsy upon consultation and agreement by the sponsor Note: In case of submitting unstained cut slides, freshly cut slides should be submitted to the testing laboratory within 14 days from when the slides are cut.

Exclusion Criteria:

1. Prior anticancer treatment within 28 days (or 5 times the half-life time, whichever is shorter) or any investigational agent within 30 days prior to the first dose of study drugs. All acute toxicities related to prior treatments must be resolved to Grade less than or equal to 1

2. Participants must have recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy

3. Participants having greater than 1+ proteinuria on urinalysis will undergo 24-h urine collection for quantitative assessment of proteinuria. Participants with urine protein greater than or equal to 1 g/24-hour will be ineligible.

4. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib

5. New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months

6. Prolongation of corrected QT (QTc) interval to greater than 480 msec

7. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug

8. Active infection (any infection requiring systemic treatment)

9. Participant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C

10. Serious nonhealing wound, ulcer, or bone fracture

11. Known intolerance to either of the study drugs (or any of the excipients)

12. History of organ allograft (Participant has had an allogenic tissue/solid organ transplant)

13. Biologic response modifiers (eg, granulocyte colony-stimulating factor) within 4 weeks before study entry. Chronic erythropoietin therapy is permitted provided that no dose adjustments were made within 2 months before first dose of study treatment

14. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial

15. Females who are pregnant or breastfeeding

16. Excluding the primary tumor leading to enrollment in this study, any other active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or cervix) within the past 24 months

17. Prior treatment with lenvatinib or any PD-1, anti-PD-L1, or anti-PD-L2 agent, excluding melanoma and NSCLC where prior treatment with one PD-1, anti-PD-L1, or anti-PD-L2 agent is allowed, and excluding RCC where prior treatment with one regimen containing an anti-PD-1/PD-L1 mAb is required.

18. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. The use of physiologic doses of corticosteroids (up to 7.5mg/d of prednisone or equivalent) may be approved after consultation with the sponsor.

19. No active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

20. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis

21. Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.

Related Conditions & MeSH terms

• Neoplasms
• Tumors

Intervention

Drug:
• Lenvatinib
Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
• Pembrolizumab
Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.

Locations

Country	Name	City	State
Norway	Haukeland Univerity Hospital	Bergen
Norway	Sørlandet Hospital	Kristiansand
Norway	Akershus Universitetssykehus HF	Lørenskog
Norway	Oslo Univerity Hospital	Oslo
Norway	Sykehuset Østfold	Sarpsborg
Spain	Hospital Universitari Germans Trias i Pujol	Badalona
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Hospital Universitario De Fuenlabrada	Fuenlabrada
Spain	Hospital La Paz	Madrid
Spain	Hospital Universitario Clinico San Carlos	Madrid
Spain	MD Anderson Cancer Center Madrid - España	Madrid
Spain	Parc Taulí Sabadell	Sabadell
Spain	Hospital Virgen de la Salud	Toledo
Spain	Hospital Universitari i Politécnic La Fe.	Valencia
United States	New York Hematology Oncology (US Onc)	Albany	New York
United States	Alaska Clinical Research Center	Anchorage	Alaska
United States	Piedmont Cancer Institue	Atlanta	Georgia
United States	Rocky Mountain Cancer Centers	Aurora	Colorado
United States	Texas Oncology-Bedford	Bedford	Texas
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Mass General Hospital	Boston	Massachusetts
United States	Rocky Mountain Cancer Centers	Boulder	Colorado
United States	The University of Chicago	Chicago	Illinois
United States	Rocky Mountain Cancer Centers	Colorado Springs	Colorado
United States	Texas Oncology	Dallas	Texas
United States	Texas Oncology (US Onc)	Dallas	Texas
United States	Texas Oncology-Denton South	Denton	Texas
United States	Rocky Mountain Cancer Centers, Site #1	Denver	Colorado
United States	Rocky Mountain Cancer Centers, Site #2	Denver	Colorado
United States	Texas Oncology-Fort Worth, Site #1	Fort Worth	Texas
United States	Texas Oncology-Grapevine	Grapevine	Texas
United States	Memorial Sloan Kettering at Westchester	Harrison	New York
United States	Comprehensive Cancer Centers of Nevada, Site #1	Henderson	Nevada
United States	Comprehensive Cancer Centers of Nevada, Site #2	Henderson	Nevada
United States	Comprehensive Cancer Centers of Nevada, Site #3	Henderson	Nevada
United States	Rocky Mountain Cancer Centers	Lakewood	Colorado
United States	Comprehensive Cancer Centers of Nevada, Site #1	Las Vegas	Nevada
United States	Comprehensive Cancer Centers of Nevada, Site #2	Las Vegas	Nevada
United States	Comprehensive Cancer Centers of Nevada, Site #3	Las Vegas	Nevada
United States	Comprehensive Cancer Centers of Nevada, Site #4	Las Vegas	Nevada
United States	Rocky Mountain Cancer Centers	Littleton	Colorado
United States	Rocky Mountain Cancer Centers	Lone Tree	Colorado
United States	Rocky Mountain Cancer Centers	Longmont	Colorado
United States	Texas Oncology-Longview Cancer Center	Longview	Texas
United States	Baptist Health Medical Group Oncology, LLC, Site #1	Miami	Florida
United States	Baptist Health Medical Group Oncology, LLC, Site #2	Miami	Florida
United States	Baptist Health Medical Group Oncology, LLC, Site #3	Miami	Florida
United States	University of Minnesota, Masonic Cancer Center	Minneapolis	Minnesota
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Arizona Oncology Associates	Oro Valley	Arizona
United States	Rocky Mountain Cancer Centers	Parker	Colorado
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Texas Oncology-Plano West	Plano	Texas
United States	Boca Raton Clinical Research Medical Center	Plantation	Florida
United States	Oregon Health & Science University	Portland	Oregon
United States	Rocky Mountain Cancer Centers	Pueblo	Colorado
United States	South Texas Accelerated Research Therapeutics, LLC	San Antonio	Texas
United States	Rocky Mountain Cancer Centers	Thornton	Colorado
United States	Arizona Oncology Associates, PC - HOPE, Site #1	Tucson	Arizona
United States	Arizona Oncology Associates, PC - HOPE, Site #2	Tucson	Arizona
United States	Arizona Oncology Associates, PC - HOPE, Site #3	Tucson	Arizona
United States	Texas Oncology-Tyler	Tyler	Texas
United States	Texas Oncology-Waco, Site #1	Waco	Texas
United States	Texas Oncology-Waco, Site #2	Waco	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Eisai Inc.	Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Norway,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib	MTD was confirmed if no more than 3 participants experience dose-limiting toxicities(DLTs)during first 3 weeks (Cycle 1) of treatment.If MTD was not confirmed at dose level,then enrollment was proceeded to next lower dose level.Sponsor and investigators reviewed all participants' safety;clinical data to jointly determine RP2D of combination of treatment.DLT may be any of following: hematological/nonhematological toxicities considered to be at least possibly related to Lenvatinib/pembrolizumab occurring during Cycle 1;Failure to administer greater than or equal to (>=) 75 percent (%) of planned dosage of lenvatinib as result of treatment-related toxicity during Cycle 1;Who discontinue treatment due to treatment-related toxicity.Greater than 2 week delay in starting Cycle 2 because of treatment-related toxicity,even if toxicity does not meet DLT criteria.Toxicity was evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03(NCI CTCAE v 4.03).	Cycle 1 (21 days)
Primary	Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) of Lenvatinib	A DLT was defined as any of the following: any of the hematological or nonhematological toxicities considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1. Failure to administer >=75% of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1. Participants who discontinue treatment due to treatment-related toxicity. Greater than 2 week delay in starting Cycle 2 because of a treatment-related toxicity, even if the toxicity does not meet DLT criteria. Toxicity was evaluated as per NCI CTCAE v 4.03.	Cycle 1 (21 days)
Primary	Objective Response Rate (ORR) Based on Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) Version 1.1 at Week 24	ORR was defined as the percentage of participants whose best overall response (BOR) was immune related complete response (irCR) or immune related partial response (irPR) based on investigator assessment according to irRECIST version 1.1. irCR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (<) 10 millimeter (mm). irPR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.	Week 24
Secondary	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)	TEAE: adverse event (AE) emerged during treatment, having been absent at pretreatment or reemerged during treatment, present at pretreatment but stopped before treatment or worsened in severity during treatment relative to pretreatment state, when AE is continuous. AE: any untoward medical occurrence in participant administered an investigational product. TEAEs were based on participants laboratory tests, regular measurement of vital signs, echocardiograms/multigated acquisition scans to assess left ventricular ejection fraction and electrocardiograms parameter values. TESAE: any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; a congenital anomaly/birth defect or was medically important due to reasons other than above criteria.	From date of first dose up to 30 days after the last dose of study drugs (Up to 74 months)
Secondary	Objective Response Rate (ORR) Based on irRECIST Version 1.1	ORR was defined as the percentage of participants whose BOR was irCR or irPR according to irRECIST version 1.1. irCR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to <10 mm. irPR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.	From date of first dose of study drug administration until immune related (irPD), development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Secondary	Progression-free Survival (PFS) Based on irRECIST Version 1.1	PFS was defined as the time from the first dose date to the date of irPD or date of death (whichever occurred first) according to irRECIST version 1.1. irPD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions was also considered progression).	From date of first dose of study drug administration to date of irPD or date of death, whichever occurred first (up to 73 months)
Secondary	Overall Survival (OS)	OS was defined as the time from the first dose date to the date of death from any cause.	From the first dose until death from any cause, up to 73 months
Secondary	Disease Control Rate (DCR) Based on irRECIST Version 1.1	DCR: percentage of participants with a confirmed irCR, irPR, or ir-stable disease (SD) (duration of irSD greater than or equal to [>=] 5 weeks). DCR was assessed on irRECIST v1.1. irCR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in their short axis to <10 mm. irPR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference baseline sum of longest diameter. irSD: neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference smallest sum diameters while on study. irPD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).	From first dose of the study drug until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Secondary	Clinical Benefit Rate (CBR) Based on irRECIST Version 1.1	CBR was defined as the percentage of participants with BOR of irCR or irPR or irdurable stable disease (irdSD) (duration of irSD >=23 weeks) [irCR + irPR + irdSD] based on irRECIST v1.1. irCR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in their short axis to <10 mm. irPR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference baseline sum of longest diameter. irSD: neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference smallest sum diameters while on study. irPD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).	From first dose date until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Secondary	Durable Stable Disease Rate (DSDR) Based on irRECIST Version 1.1	Durable SD rate is defined as the percentage of participants whose observed BOR is irSD and the duration of irSD is >=23 weeks based on irRECIST v1.1.	From first dose date until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Secondary	Duration of Objective Response (DOR) Based on irRECIST Version 1.1	DOR: time from date of first observation of response (irPR or irCR) to date of the first observation of progression based on irRECIST 1.1, or date of death, whatever the cause. irCR: disappearance of all target and non-target lesions. All pathological (whether target or non-target) must have reduction in their short axis <10 mm. irPR: at least 30% decrease in sum of diameter (SOD) of target lesions, taking as reference baseline sum diameters. irPD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in SOD of target lesions, taking as reference smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.	First documentation of irCR or irPR until first documentation of progression or death (up to 73 months)
Secondary	Phase 1b: Plasma Concentrations of Lenvatinib	Observed plasma concentration of Lenvatinib was reported here quantified by liquid chromatography with tandem mass spectrometry (LCMS/MS) method.	Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post dose; Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours post dose, Cycle 2 Day 1: predose, 2-12 hour postdose and Cycles 3,4,5,6 Day 1 predose (Cycle length =21 days)
Secondary	Plasma Concentrations of Lenvatinib	Observed plasma concentration of Lenvatinib was reported here quantified by LCMS/MS method.	Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post dose; Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours post dose, Cycle 2 Day 1: predose, 2-12 hour postdose and Cycles 3,4,5,6 Day 1 predose (Cycle length =21 days):